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A B S T R A C T
Objective. The objective of this study is to evaluate the safety and feasibility of the AZUR hydrogel-polymer coated
platinum coil (hydrocoil) for vascular occlusion in patients with congenital cardiovascular disease (CCVD).
Design. Retrospective case review.
Patients. Eight patients with CCVD who underwent attempted vascular occlusion procedure with the hydrocoil at
the University of Michigan between January 1, 2008 and March 1, 2011. Median patient age was 1.6 years (range
0.6–27.5 years) and median weight was 10.6 kg (3.9–74.8 kg).
Outcome Measures. Complete vascular occlusion of the target vessel was assessed at procedural completion with
angiography and noninvasive imaging at follow-up. Key procedural variables and adverse events were also evaluated.
Results. A total of 21 hydrocoils were successfully placed in seven vessels, in six patients. Vessels included four (57%)
veno-venous collaterals, two (29%) aortopulmonary collaterals, and one (14%) main pulmonary artery. Hydrocoils
could not be placed successfully in two patients, including one bafﬂe leak and one veno-venous collateral. Pretreat-
ment of the hydrocoil with steam to soften the coil, prior to vascular introduction, increased the likelihood of
successful implant (100% vs. 60%). Complete occlusion was observed in 100% of vessels either at the time of
catheterization or at follow-up. There were no complications attributable to the hydrocoil.
Conclusions. Hydrocoils are safe and effective devices that can be utilized for vascular occlusion in a variety of blood
vessels in patients with CCVD. Coil pretreatment may increase the likelihood of procedural success.
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Introduction
The armamentarium of materials and devicesavailable to the pediatric interventional
cardiologist for closure of unwanted congenital
or acquired vascular connections has grown
exponentially in recent years. Although once
limited to a polyvinyl alcohol Ivalon plug,
closure options now include pushable stainless
steel coils, detachable coils of various materials,
vascular plugs, embolization glue, microspheres,
and others.1 The hydrogel-coated expandable
embolization coil only recently has begun to be
utilized in the ﬁeld of congenital vascular occlu-
sion, although it has been widely applied in the
treatment of intracranial aneurysm starting in
2002.2–5
The AZUR peripheral hydrocoil embolization
system (hydrocoil, Terumo Medical Corporation,
Somerset, NJ, USA) combines a hydrogel-coated
platinum coil with a screwless proprietary delivery
system, offering numerous advantages over tradi-
tional stainless steel pushable coils. The hydrocoil
provides for improved volumetric ﬁlling of vessels,
mechanical occlusion that does not depend upon
thrombus formation, increased delivery control,
and enhanced reconstruction of the arterial wall,
including earlier neointimal formation and healing
compared with noncoated coils.6–10 Platinum
hydrocoils are available in detachable or pushable
delivery forms, in 0.018″ and 0.035″ wire diam-
eters, as helical or framing coils, and in a large
number of lengths and loop diameters. Use of the
hydrocoil in congenital cardiovascular disease has
not been reported to date. We sought to describe
our experience with the hydrocoil for vascular
occlusion in congenital cardiovascular disease at
the University of Michigan.
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Materials and Methods
A query of the cardiac catheterization laboratory
database identiﬁed all patients with congenital car-
diovascular disease who underwent attempted
vascular occlusion procedure with a hydrocoil
between January 1, 2008 and March 1, 2011.
Demographic and medical characteristics were
identiﬁed and key procedural components were
recorded, including target blood vessel character-
istics, attempts at vascular occlusion with alter-
native device(s), hydrocoil pretreatment, and
procedural success. All original angiograms were
reviewed (BHG). Technical success was deﬁned as
complete occlusion at the time of the procedure or
appropriate coil position with no embolization to,
or obstruction of, nontarget vessels. Complete
occlusion was deﬁned as complete angiographic
occlusion at the time of the procedure or if subse-
quent imaging demonstrated a lack of residual ﬂow
in the target vessel. Median time from coil place-
ment to follow-up imaging study documenting
complete vascular occlusion was determined, when
complete occlusion was not achieved in the cath-
eterization laboratory. Complications of the proce-
dure were recorded.
Cardiac catheterizations were performed in
routine fashion under procedural sedation or
general anesthesia according to provider prefer-
ence. Hydrocoil sizing was determined based upon
target vessel minimal diameter at intended location
of deployment, with the goal of placing a coil with
diameter approximately equaling 1.5 to 2.5 times
the target vesselminimal diameter. Pretreatment of
the coil with steam was performed based upon the
preference of the provider. Coil deployment was
performed according to standard techniques.
Results
Eight patients met inclusion criteria for the study.
Demographic and medical characteristics are
detailed in Table 1. A total of 21 hydrocoils were
placed in seven blood vessels, in six patients. All
implanted hydrocoils were 0.018″ in diameter.
Hydrocoil implantation was not successfully per-
formed in two patients. The median patient age
was 1.6 years (range 0.6–27.5 years) and median
weight was 10.6 kg (range 3.9–74.8 kg). Hydrocoil
deployment was performed in a variety of blood
vessels including venous collaterals (57%), aortop-
ulmonary collaterals (29%), and other vessels
(14%). Unsuccessful implantations occurred in
one veno-venous collateral and one Senning bafﬂe
leak.
Results of hydrocoil implantation are shown in
Table 2. Technical success was achieved in all
patients in whom a hydrocoil was released. Hydro-
coil delivery resulted in complete occlusion in the
catheterization laboratory in 67% of cases. Com-
plete occlusion was achieved in the remaining
33% of cases at a median follow-up time of 8.3
months. No patients have demonstrated evidence
of recanalization (deﬁned by return of ﬂow in
the target vessel) by follow-up imaging studies.
Therefore, complete vascular occlusion was
achieved in 100% of patients who received a
hydrocoil.
Venous Collaterals
A total of 16 hydrocoils were delivered in four
vessels in three patients. Venous collateral vessels
included three veno-venous collaterals and one
veno-atrial collateral. All patients had single ven-
tricle physiology and were at the post-Fontan
stage. Complete occlusion was documented at
catheterization in 75% of these venous collaterals.
The remaining vessel was documented to be com-
pletely occluded by imaging at follow-up. Occlu-
sion of a veno-venous collateral using a hydrocoil
was attempted in one additional patient but the
coil was not deployed because of failure to achieve
Table 1. Demographic and Medical Characteristics of the Study Population
Patient
No. Sex
Age
(Years)
Weight
(Kg) Diagnosis Indication
1 F 27.5 53.7 SVC occlusion Cyanosis
2 F 17.7 60.3 Ebstein’s s/p Fontan Cyanosis
3 F 0.6 7.2 TOF/PA/MAPCA Dual supply collateral
4 F 1.8 12.3 Tricuspid atresia s/p Fontan Cyanosis
5 F 0.2 3.9 Heterotaxy, single ventricle physiology s/p PA
band and aortopulmonary shunt
Pulmonary overcirculation
6 M 1.0 7.5 TOF/PA/MAPCA Dual supply collateral
7 M 14.5 74.8 HLHS s/p Fontan Cyanosis
8 M 1.4 8.9 {S,L,L}, VSD, CoA s/p Senning/arterial switch Cyanosis
CoA, coarctation of the aorta; HLHS, hypoplastic left heart syndrome; PA, pulmonary artery; SVC, superior vena cava; TOF/PA/MAPCA, tetralogy of Fallot with
pulmonary atresia and multiple aortopulmonary collateral arteries; VSD, ventricular septal defect; M, male; F, female; s/p, status post.
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the desired coil conﬁrmation. Figure 1 demon-
strates a large tortuous veno-venous collateral that
has been completely occluded following place-
ment of three hydrocoils in a 14-year-old male
with hypoplastic left heart syndrome palliated to
Fontan physiology.
Aortopulmonary Collaterals
A total of two hydrocoils were delivered in two
vessels in two patients. Both patients had tetralogy
of Fallot with pulmonary atresia and multiple aor-
topulmonary collateral vessels. Complete occlu-
sion was documented at catheterization in one of
these aortopulmonary collaterals. The remaining
vessel was documented to be completely occluded
by imaging at follow-up. Figure 2 demonstrates an
aortopulmonary collateral that has been com-
pletely occluded following placement of a single
hydrocoil in a 6-month-old female with tetralogy
of Fallot, pulmonary atresia, and multiple aortop-
ulmonary collateral arteries status post unifocal-
ization procedure.
Other Vessels
Two additional vascular occlusion procedures were
undertaken using the hydrocoil. In one case,
closure of a bafﬂe leak with associated right-to-
left shunt was attempted in a 16-month-old pat-
ient with (S,L,L) transposition, ventricular septal
defect, and coarctation status post coarctation
repair, ventricular septal defect closure, Senning
bafﬂe, and arterial switch operation. Although the
coil could be delivered to the desired location, its
relatively straight conformation (this deployment
was prior to our experience with coil pretreat-
ment), ﬂoppy character, and location immediately
adjacent to the mitral valve precluded the opera-
tors from safely deploying the hydrocoil. In the
other case, deﬁnitive occlusion of a banded main
pulmonary artery was attempted following the
development of transfusion-dependent hemolysis
after deployment of a pushable stainless steel
Gianturco coil (Cook Medical Inc., Bloomington,
IN, USA) in a 2-month-old with complex hetero-
taxy syndrome and single ventricle physiology
Table 2. Results of Hydrocoil Vascular Occlusions
Patient
No.
Target
Vessel
Vessel
Diameter (mm)
Coil Loop
Diameter(s) (mm)
No. of Coils
Implanted
Coil
Pretreated
CO on
Angio or F/u
1 VVC 1.7 3 0 No N/A
2 VVC 17.4 8, 10, 15 11 No Yes
3 APC 1.8 4 1 Yes Yes
4 VVC 2.6 4 2 Yes Yes
5 MPA 4.0 4 3 Yes Yes
6 APC 1.5 4 1 No Yes
7 VVC 6.3 8, 10 3 No Yes
8 Baffle leak 4.5 10 0 No N/A
Angio, angiogram; APC, aortopulmonary collateral; CO, complete occlusion of target vessel; F/u, follow-up noninvasive imaging; MPA, main pulmonary artery;
Vessel diameter, minimal diameter of target vessel; VVC, veno-venous collateral; N/A, not applicable.
A B
Figure 1. Large and tortuous veno-venous collateral in a 14-year-old patient with hypoplastic left heart syndrome palliated
to Fontan physiology, who presented with increased cyanosis. Panel A shows the collateral in the anteroposterior projection,
prior to intervention. Panel B demonstrates complete occlusion of the veno-venous collateral following deployment of three
hydrocoils.
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status post main pulmonary artery banding (sub-
total pulmonary artery ligation) and aortopulmo-
nary shunt placement. In this case, three
hydrocoils were deployed in the main pulmonary
artery, between the pulmonary valve and surgical
band, nesting within the space partially occupied
by the existing stainless steel coil (Figure 3). Com-
plete vascular occlusion was observed angio-
graphically and hemolysis later resolved.
Coil Pretreatment
In some instances, the hydrocoil was “pretreated”
with steam to promote coil softening and reacqui-
sition of a helical shape prior to exposure to the
blood stream (Figure 4). This process allows the
hydrocoil to assume immediately its intended
“tight” helical conformation during deployment
rather than to be delivered as a “loose” helical coil,
assuming a tight helical conformation once in the
vascular space for several minutes. We felt that
pretreatment was particularly advantageous in
cases in which the target vessel was small, short, or
tortuous and in which the margin for error with
coil delivery was small. Successful hydrocoil
implantation occurred in 100% of cases in which a
pretreatment strategy was employed and in 60%
A B C
Figure 2. Aortopulmonary collateral artery in a 6-month-old patient with tetralogy of Fallot, pulmonary atresia, and multiple
aortopulmonary collaterals, following unifocalization of important single-supply collateral vessels. Panel A depicts the
aortopulmonary collateral arising from the descending aorta and connecting to the left lower lobe pulmonary artery, prior to
intervention. In panel B, a single hydrocoil has been delivered with reduced but persistent aortopulmonary collateral flow. At
catheterization 8 months later (panel C), following right ventricle to pulmonary artery conduit implantation, no evidence of
persistent collateral flow is identified in an aortogram.
A B C
Figure 3. Main pulmonary artery in a 2-month-old patient with complex single ventricle anatomy status post pulmonary
artery band (subtotal pulmonary artery ligation) and aortopulmonary shunt placement. Following the development of
pulmonary overcirculation, a single pushable stainless steel Gianturco coil was deployed within the region between the
stenotic native pulmonary valve annulus and the main pulmonary artery band, resulting in reduced but not eliminated blood
flow (panel A). However, because of the development of transfusion-dependent hemolysis, the patient returned to the
catheterization laboratory for placement of three hydrocoils, which resulted in complete vascular occlusion and cessation of
active hemolysis (panels B & C).
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of cases in which the hydrocoil was implanted as it
comes “off the shelf.”
Complications
There were no periprocedural complications in
the eight patients in whom hydrocoil implantation
was attempted. There were no coil embolizations
to nontarget vessels, obstruction of nontarget
vessels, or hemolysis.
Discussion
Although hydrogel-coated platinum coils have
been used by interventional radiologists and neu-
roradiologists for nearly a decade, their use in con-
genital cardiovascular disease has not been
described previously. In this report, we describe
the implantation of hydrocoils in a wide range of
patient ages, congenital heart defects, and target
vessels, including venous collaterals, aortopulmo-
nary collaterals, and other structures. We encoun-
tered no complications and had a 100% target
vessel complete occlusion rate when combining
procedural angiographic and follow-up noninva-
sive imaging end points.
Recently, a number of reports have been pub-
lished verifying the efﬁcacy of newly introduced
occlusion devices in the ﬁeld of congenital car-
diovascular disease, including the Amplatzer
ductal occluder and vascular plug series (AGA
Medical Corporation, Plymouth, MN, USA).11–13
The Amplatzer vascular plugs I & II have been
shown to deliver high rates of complete vascular
occlusion in a variety of target vessels without
major complications.12,13 The second generation
vascular plug was shown to be particularly useful
for occlusion of high-ﬂow tubular lesions, such as
patent ductus arteriosus, aortopulmonary collat-
erals, and arteriovenous malformations.13 In con-
trast to the vascular plug, which requires either a
stiff guide catheter or long sheath for delivery,
the hydrocoil may be delivered through a micro-
catheter, enabling access to more tortuous and
difﬁcult to reach target vessels. The hydrogel
coating allows a 0.018″ diameter coil to provide
greater volumetric ﬁlling, once fully hydrated,
than a standard 0.035″ diameter coil (approxi-
mately equivalent to a 0.04″ diameter coil). Thus,
the hydrocoil is particularly effective in occlusion
of vessels that are difﬁcult to access with a cath-
eter or sheath large enough through which to
deliver most occluding devices (such as the vas-
cular plug or a 0.035″ diameter coil). In our
series, there were several cases in which vascular
occlusion could not have been efﬁciently
achieved (if occlusion could have been achieved
at all) without the ability to deliver the hydro-
coil(s) via a microcatheter.
A second signiﬁcant advantage of the hydrocoil
is the control with which it can be delivered, repo-
sitioned, and released. The delivery “wire” and
platinum hydrocoil are one-piece “off the shelf”
with no proﬁle change at the connection site. The
densely radio-opaque nature of the platinum coil
makes the connection site obvious on ﬂuoroscopy.
Release of the hydrocoil is achieved almost in-
stantaneously upon activation of a proprietary
“handle” which delivers a small electric current via
the delivery wire to the wire-coil connection site
and facilitates a local electrolytic reaction. This
degree of delivery control accounted for the lack
of coil embolization or other device complications
encountered in our series. Although our series is
small, the 0% complication rate is far below that
reported in previous large series of coil- and
device-associated transcatheter vascular occlusion
procedures.11,14,15
There are several other important advantages of
the hydrocoil as a vascular occlusion device. As a
platinum-based coil, the hydrocoil does not gen-
erate signiﬁcant artifact on magnetic resonance
A
B
Figure 4. Effect of coil pretreatment with steam on coil
conformation prior to vascular introduction. Panel A demon-
strates a hydrocoil advanced via a microcatheter without
any pretreatment, as it would be used “off the shelf.” In
panel B, the coil has been treated with steam prior to intro-
duction into the microcatheter, allowing it to assume a more
helical conformation.
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imaging, a major drawback of the stainless steel
coil in the current imaging era.16 Meanwhile, to
date, there are no reports in the literature associ-
ating the hydrocoil with intravascular hemolysis.
In fact, in our series, the hydrocoil was utilized to
successfully treat ongoing transfusion-dependent
hemolysis by completely occluding a main pulmo-
nary artery that had been partially occluded with a
Gianturco stainless steel coil. Additionally, we
noted the development of late complete occlusion
in one patient with an aortopulmonary collateral
and incomplete angiographic occlusion at hydro-
coil implantation. We believe this is due to con-
tinued coil hydration, beyond the initial 15–20
minutes of rapid coil hydration upon exposure to
the bloodstream, and is an added beneﬁt of the
hydrocoil, when compared with a standard stain-
less steel coil. Moreover, the modality of hydrocoil
vascular occlusion—mechanical (volumetric)
luminal obstruction, rather than thrombo-
occlusion—ought to lower the risk of postproce-
dural thromboembolism, compared with
alternative methods of vascular occlusion.7,8
One potential drawback of the hydrocoil is the
relatively stiff nature of the coil in its dehydrated
form (off the shelf) prior to exposure to the blood-
stream. This relatively stiff and straight nature of
the coil could preclude successful delivery and
implantation in small and tortuous target vessels,
but ex vivo prehydration of the hydrocoil with
steam modiﬁes the hydrocoil such that it assumes
its ultimate helical shape (see Figure 4). The coil is
then loaded into the delivery catheter and assumes
a tight helical shape immediately upon advance-
ment into the vessel. Pretreatment does not risk
overhydration of the hydrogel coating; the 0.018″
coil can always be introduced into a microcatheter
after this process. In fact, in our experience, the
0.018″ hydrocoil could still be removed from the
body via a microcatheter after coil pretreatment
and an additional 5–10 minutes of hydration
during coil positioning within the target vessel.
Although we did not experience difﬁculty with coil
removal via a microcatheter, the hydrocoil even-
tually becomes hydrated beyond a diameter at
which removal through the microcatheter can be
accomplished. This can happen as early as 10–15
minutes after exposure to the bloodstream. If this
does happen, however, the hydrocoil and micro-
catheter combination can be removed together, via
the guiding catheter, to facilitate successful
removal of an unreleased hydrocoil.
In comparing devices for vascular occlusion, it
is important to evaluate relative device costs.
While the stainless steel Gianturco coil will always
be less expensive than newly introduced more
complex and technically advanced devices, this
comparison is probably less relevant in the present
era. Indeed, when comparing the hydrocoil with
other vascular occlusion devices approved in the
last decade, the hydrocoil is equivalent in cost to
the Amplatzer vascular plug II, well less expensive
than the Amplatzer ductal occluder and slightly
more expensive than the Flipper detachable coil
(Cook Medical Inc., Bloomington, IN, USA).
Conclusions
In summary, we found hydrocoils to be safe and
effective devices for vascular occlusion in a variety
of circumstances routinely encountered in the
treatment of patients with congenital cardiovascu-
lar disease. Hydrocoils offer several important
advantages over existing occlusion devices includ-
ing smaller delivery proﬁle, enhanced delivery
control, improved volumetric ﬁlling of vessels,
earlier vascular healing, and decreased risk for
hemolysis. Hydrocoil pretreatment may increase
the likelihood of successful coil deployment.
While not ideal for all target vessels, the hydrocoil
signiﬁcantly augments the existing vascular occlu-
sion “tool set” of the pediatric interventional
cardiologist.
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